Review of outcomes after cessation of gonadotropin-releasing hormone agonist treatment of girls with precocious puberty

Paul Thornton, Lawrence A. Silverman, Mitchell E. Geffner, E. Kirk Neely, Errol Gould, Theodore M. Danoff

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Although gonadotropin-releasing hormone agonists (GnRHa) have been the standard of care of central precocious puberty (CPP) management for many years, there are still questions about the long-term consequences of treatment. With increased utilization of GnRHa treatment, it is now possible to assess posttreatment outcomes in the immediate posttreatment period and into adulthood. This literature review reports on the long-term effects of GnRHa therapy in girls with CPP after therapy has been discontinued. Published reports confirm the reversibility of hypothalamic-pituitary-ovarian axis suppression in females after cessation of GnRHa therapy, with the majority of patients achieving ovulatory menstrual cycles of normal timing and duration. GnRHa therapy does not appear to induce polycystic ovary syndrome or have long-term negative repercussions on either bone mineral density or body composition. Evidence is currently insufficient to identify agent-specific differences in outcomes, reproductive function, and health of offspring.

Original languageEnglish (US)
Pages (from-to)306-317
Number of pages12
JournalPediatric Endocrinology Reviews
Volume11
Issue number3
StatePublished - Mar 1 2014
Externally publishedYes

Fingerprint

Precocious Puberty
Gonadotropin-Releasing Hormone
Therapeutics
Polycystic Ovary Syndrome
Reproductive Health
Standard of Care
Menstrual Cycle
Body Composition
Bone Density

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism

Cite this

Thornton, Paul ; Silverman, Lawrence A. ; Geffner, Mitchell E. ; Neely, E. Kirk ; Gould, Errol ; Danoff, Theodore M. / Review of outcomes after cessation of gonadotropin-releasing hormone agonist treatment of girls with precocious puberty. In: Pediatric Endocrinology Reviews. 2014 ; Vol. 11, No. 3. pp. 306-317.
@article{e13d2309a06148699e028750570548db,
title = "Review of outcomes after cessation of gonadotropin-releasing hormone agonist treatment of girls with precocious puberty",
abstract = "Although gonadotropin-releasing hormone agonists (GnRHa) have been the standard of care of central precocious puberty (CPP) management for many years, there are still questions about the long-term consequences of treatment. With increased utilization of GnRHa treatment, it is now possible to assess posttreatment outcomes in the immediate posttreatment period and into adulthood. This literature review reports on the long-term effects of GnRHa therapy in girls with CPP after therapy has been discontinued. Published reports confirm the reversibility of hypothalamic-pituitary-ovarian axis suppression in females after cessation of GnRHa therapy, with the majority of patients achieving ovulatory menstrual cycles of normal timing and duration. GnRHa therapy does not appear to induce polycystic ovary syndrome or have long-term negative repercussions on either bone mineral density or body composition. Evidence is currently insufficient to identify agent-specific differences in outcomes, reproductive function, and health of offspring.",
author = "Paul Thornton and Silverman, {Lawrence A.} and Geffner, {Mitchell E.} and Neely, {E. Kirk} and Errol Gould and Danoff, {Theodore M.}",
year = "2014",
month = "3",
day = "1",
language = "English (US)",
volume = "11",
pages = "306--317",
journal = "Pediatric Endocrinology Reviews",
issn = "1565-4753",
publisher = "YS Medical Media Ltd.",
number = "3",

}

Review of outcomes after cessation of gonadotropin-releasing hormone agonist treatment of girls with precocious puberty. / Thornton, Paul; Silverman, Lawrence A.; Geffner, Mitchell E.; Neely, E. Kirk; Gould, Errol; Danoff, Theodore M.

In: Pediatric Endocrinology Reviews, Vol. 11, No. 3, 01.03.2014, p. 306-317.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Review of outcomes after cessation of gonadotropin-releasing hormone agonist treatment of girls with precocious puberty

AU - Thornton, Paul

AU - Silverman, Lawrence A.

AU - Geffner, Mitchell E.

AU - Neely, E. Kirk

AU - Gould, Errol

AU - Danoff, Theodore M.

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Although gonadotropin-releasing hormone agonists (GnRHa) have been the standard of care of central precocious puberty (CPP) management for many years, there are still questions about the long-term consequences of treatment. With increased utilization of GnRHa treatment, it is now possible to assess posttreatment outcomes in the immediate posttreatment period and into adulthood. This literature review reports on the long-term effects of GnRHa therapy in girls with CPP after therapy has been discontinued. Published reports confirm the reversibility of hypothalamic-pituitary-ovarian axis suppression in females after cessation of GnRHa therapy, with the majority of patients achieving ovulatory menstrual cycles of normal timing and duration. GnRHa therapy does not appear to induce polycystic ovary syndrome or have long-term negative repercussions on either bone mineral density or body composition. Evidence is currently insufficient to identify agent-specific differences in outcomes, reproductive function, and health of offspring.

AB - Although gonadotropin-releasing hormone agonists (GnRHa) have been the standard of care of central precocious puberty (CPP) management for many years, there are still questions about the long-term consequences of treatment. With increased utilization of GnRHa treatment, it is now possible to assess posttreatment outcomes in the immediate posttreatment period and into adulthood. This literature review reports on the long-term effects of GnRHa therapy in girls with CPP after therapy has been discontinued. Published reports confirm the reversibility of hypothalamic-pituitary-ovarian axis suppression in females after cessation of GnRHa therapy, with the majority of patients achieving ovulatory menstrual cycles of normal timing and duration. GnRHa therapy does not appear to induce polycystic ovary syndrome or have long-term negative repercussions on either bone mineral density or body composition. Evidence is currently insufficient to identify agent-specific differences in outcomes, reproductive function, and health of offspring.

UR - http://www.scopus.com/inward/record.url?scp=84899564175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899564175&partnerID=8YFLogxK

M3 - Article

C2 - 24719967

AN - SCOPUS:84899564175

VL - 11

SP - 306

EP - 317

JO - Pediatric Endocrinology Reviews

JF - Pediatric Endocrinology Reviews

SN - 1565-4753

IS - 3

ER -